Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 180 of 6351
-
Can a TROP2-targeting drug shrink hard-to-treat small bowel cancer?
Disease control Not yet recruitingSmall bowel adenocarcinoma is a rare cancer with a poor prognosis. For patients with locally advanced or metastatic disease, the usual first treatment is chemotherapy with platinum-based combinations such as FOLFOX or CapeOX. However, once the cancer grows after this treatment or…
Phase 2 • Sponsor: National Cancer Center, Japan • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can a smart drug shrink rare gynecologic tumors?
Disease control Not yet recruitingThe ARCANA trial (LACOG 1724) is a single-arm, non-randomized, multi-center, parallel, two-cohort Phase II clinical study designed to evaluate the efficacy and safety of sacituzumab tirumotecan (sac-TMT, MK-2870) as a second-line or subsequent treatment in patients with advanced …
Phase 2 • Sponsor: Latin American Cooperative Oncology Group • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a tailored drug combo improve early response in chronic myeloid leukemia?
Disease control Not yet recruitingThis is a multi-center, prospective, non-randomized but stratified interventional phase II study of newly diagnosed CML patients in chronic phase. All patients will be treated with asciminib 80 mg QD. Patients with unfavorable risk factors will commence dasatinib 80 mg 5 days/wee…
Phase 2 • Sponsor: Prof. Dr. med. Andreas Hochhaus • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Could cash incentives keep mothers in addiction treatment and save lives?
Disease control Not yet recruitingOverdose is a national top-three leading cause of pregnancy-associated death, and maternal substance use disorder (SUD) accounts for an estimated $1.5 billion in healthcare spending each year. Treatment with medication and behavioral therapy lowers morbidity and overdose risk. Ho…
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Can a Two-Pronged drug attack Hard-to-Treat tumors?
Disease control Not yet recruitingThe Phase 1 clinical study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of BD200 in adult participants with advanced solid cancers. This is an open-label study consisting of two-parts: Part A Dose Escala…
Phase 1 • Sponsor: Biolojic Design Ltd. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
One tiny incision: could robotic surgery transform breast cancer treatment?
Disease control Not yet recruitingThis study is testing a new, less invasive way to perform breast cancer surgery using a single-port robotic system (a robot-assisted surgical tool made in China, called the Shurui SR-ENS-600). The robot works through one small hidden incision (about 3-4 cm) in the armpit or under…
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Hormone blocker plus targeted drug shows promise against tough uterine cancer
Disease control Not yet recruitingThis phase II trial tests how well elacestrant with everolimus works for the treatment of estrogen receptor (ER) positive endometrial cancer that has come back after a period of improvement (recurrent), that may have spread from where it first started to nearby tissue, lymph node…
Phase 2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
A new heart valve without Open-Heart surgery: can it help High-Risk patients?
Disease control Not yet recruitingThis is a prospective, multicenter, single-arm clinical investigation designed to evaluate the safety and performance of an investigational transcatheter aortic valve replacement system in patients with symptomatic severe native aortic valve stenosis who are considered appropriat…
Sponsor: Onecrea Medical Inc. • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a targeted biologic outperform standard care for a rare blistering disease?
Disease control Not yet recruitingThis quasi-experimental study aims to compare the effectiveness and safety of rituximab combined with corticosteroids versus the standard regimen of oral corticosteroids plus azathioprine in patients with moderate to severe pemphigus vulgaris. Pemphigus vulgaris is a rare autoim…
Early phase 1 • Sponsor: Khyber Teaching Hospital • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
A simple pill may supercharge antibiotics against stubborn bone infections
Disease control Not yet recruitingOsteoarticular infections (OAIs) are common, with Streptococcus spp. and Enterococcus spp. being the second most common causative pathogens after Staphylococcus aureus. High-dose oral amoxicillin is recommended as first-line treatment for susceptible infections caused by Streptoc…
Phase 3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a new drug combo revive immunotherapy for lymphoma?
Disease control Not yet recruitingThis is an open-label clinical study designed to evaluate the efficacy of Stapokibart combined with immune checkpoint inhibitors in patients with relapsed/refractory lymphoma. Approximately 20 patients with relapsed/refractory lymphoma who have failed prior immune checkpoint inhi…
Phase 2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can a new migraine drug stop the dizzy spells?
Disease control Not yet recruitingVestibular migraine is a common condition that causes repeated episodes of dizziness or vertigo, often with migraine headaches, sensitivity to light and sound, and nausea. It affects 1% to 2.7% of the general population and is one of the most frequent diagnoses in dizziness clini…
Phase 2 • Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New CAR T-Cell combo trial targets tough hodgkin lymphoma in youth
Disease control Not yet recruitingPatients with poor risk classical Hodgkin Lymphoma (cHL) will undergo myeloablative chemotherapy (MAC) with autologous stem cell transplantation (AutoHSCT) and subsequently receive autologous CD30+ CAR T-cells.
Phase 1/2 • Sponsor: New York Medical College • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug MHB018A aims to reduce eye bulging in thyroid eye disease
Disease control Not yet recruitingThe primary objective of this study is to evaluate the efficacy of MHB018A injection compared with placebo in participants with chronic moderate-to-severe TED.
Phase 3 • Sponsor: Minghui Pharmaceutical (Hangzhou) Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Blood test may let cancer patients take safe breaks from immunotherapy
Disease control Not yet recruitingThis is a multicenter, open-label, randomized (1:1) trial designed to evaluate whether ctDNA-guided interruption of immune-checkpoint inhibitor (ICI) therapy provides comparable survival to standard of care (SoC) continuous ICI therapy in patients with histologically confirmed ad…
Sponsor: Natera, Inc. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Magic mushroom compound may turn back the biological clock — a trial investigates
Knowledge-focused Not yet recruitingThe LONG-LIFE study is a randomized Phase I, dose-ranging trial designed to evaluate whether psilocybin impacts aging-related biomarkers, cognitive function, and purpose/meaning in life in medically stable older adults. Up to 50 participants will be enrolled aged 60-80 who will …
Phase 1 • Sponsor: Charles Raison • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Can a gene therapy rewire brain cells to ease Parkinson's?
Disease control Not yet recruitingThis study aims to evaluate the safety, tolerability, and preliminary efficacy of ZR001, a novel chemogenetic gene therapy product, in patients with moderately advanced Parkinson's disease (PD). ZR001 is administered via stereotactic injection into the bilateral substantia nigra,…
Phase 1 • Sponsor: Qianfoshan Hospital • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can a gentler dose of zanubrutinib keep CLL at bay in the very elderly?
Disease control Not yet recruitingThis phase II, open-label, multicenter study evaluates zanubrutinib in patients aged 80 years and older with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who require treatment. CLL and SLL are slow-growing blood cancers that mainly …
Phase 2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Special MRI may help surgeons remove more brain tumor
Disease control Not yet recruitingThis phase III trial compares pH weighted chemical exchange saturation transfer (CEST) magnetic resonance imaging (MRI)-based surgical resections to standard of care surgical resections for the treatment of patients with glioblastoma. Standard of care therapy for glioblastoma is …
Phase 3 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Muscle-Saving supplement may shield seniors from Weight-Loss drug side effect
Disease control Not yet recruitingThis randomized, double-blind, placebo-controlled trial will evaluate whether daily calcium beta-hydroxy-beta-methylbutyrate (calcium-HMB) plus vitamin D3 preserves muscle mass, physical function, and resting metabolism in adults aged 65 to 85 years with type 2 diabetes who are n…
Phase 2 • Sponsor: Vanderbilt University Medical Center • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC